References
- Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51:2–15.
- Vena GA, Chieco P, Posa F, et al. Epidemiology of dermatophytoses: retrospective analysis from 2005 to 2010 and comparison with previous data from 1975. New Microbiol. 2012;35:207–213.
- Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2014;41:374–388.
- Gupta AK, Paquet M. Management of onychomycosis in Canada in 2014. J Cutan Med Surg. 2015;19:260–273.
- Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol Online J. 2016;7:77–86.
- Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol. 2013;31:544–554.
- Lecha M, Effendy I, Feuilhade de Chauvin M, et al. Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol JEADV. 2005;19:25–33.
- Moura CS, Acurcio FA, Belo NO. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm. 2009;12:266–272.
- Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;48:1441–1458.
- Jazbar J, Locatelli I, Horvat N, et al. Clinically relevant potential drug-drug interactions among outpatients: a nationwide database study. Res Soc Adm Pharm RSAP. 2017:1–9. [Epub Ahead of print].
- Pr LAMISIL* (terbinafine hydrochloride) 250 mg tablets (expressed as base) topical cream 1% w/w (10 mg/g) topical spray solution 1% w/w (10 mg/g) [internet]. Health Canada drug product database; [cited 2018 Feb 28]; Available from: https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
- EMEA-001259-PIP02-13-M01 [Internet]. European medicines agency; [cited 2018 Feb 28]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001259-PIP02-13-M01/pip_001049.jsp&mid=WC0b01ac058001d129&source=homeMedSearch
- Prokanazol [Internet]. European medicines agency; [cited 2018 Feb 26]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Prokanazol/human_referral_000003.jsp&mid=WC0b01ac0580024e9a
- Questions and answers on the referral for Prokanazol capsules containing itraconazole 100 mg [Internet]. European medicines agency; [cited 2018 Feb 26]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Prokanazol_29/WC500006883.pdf
- Fluconazol Tiefenbacker 50 mg, 100 mg, 150 mg, 200 mg capsules, hard, INN-Fluconazole [Internet]. European medicines agency; [cited 2018 Feb 26]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Fluconazol_Tiefenbacher_29/WC500010808.pdf
- Posaconazole [Internet]. European medicines agency; [cited 2018 Feb 26]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000610/WC500037781.pdf
- EMEA-001627-PIP01-14 [Internet]. European medicines agency; [cited 2018 Feb 26]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001627-PIP01-14/pip_001300.jsp&mid=WC0b01ac058001d129
- Canazole [Internet]. European medicines agency; [cited 2018 Feb 26]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Canazole/human_referral_000264.jsp&mid=WC0b01ac05805c516f
- Novartis. LAMISIL (terbinafine hydrochloride) Tablets, 250 mg [Internet]. Drugs@FDA; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf **
- Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J Am Acad Dermatol. 2002;47:467–484.
- Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6–13.
- Virani A, Mailis A, Shapiro LE, et al. Drug interactions in human neuropathic pain pharmacotherapy. Pain. 1997;73:3–13.
- Abdel-Rahman SM, Marcucci K, Boge T, et al. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine. Drug Metab Dispos Biol Fate Chem. 1999;27:770–775.
- Shapiro L, Knowles S, Shear N. Drug interactions of clinical significance for the dermatologist: recognition and avoidance. Am J Clin Dermatol. 2003;4:623–639.
- Moton A, Ma L, Krishna G, et al. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin. 2009;25:701–707.
- Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825–834.
- Teitelbaum ML, Pearson VE. Imipramine toxicity and terbinafine. Am J Psychiatry. 2001;158:2086.
- Van der Kuy PH, Hooymans PM. Nortriptyline intoxication induced by terbinafine. Bmj. 1998;316:441.
- Bebawi E, Jouni SS, Tessier -A-A, et al. A metoprolol-terbinafine combination induced bradycardia. Eur J Drug Metab Pharmacokinet. 2015;40:295–299.
- Sheikh AR, Westley I, Sallustio B, et al. Interaction of terbinafine (anti-fungal agent) with perhexiline: a case report. Heart Lung Circ. 2014;23:e149–51.
- O’Reardon JP, Hetznecker JM, Rynn MA, et al. Desipramine toxicity with terbinafine. Am J Psychiatry. 2002;159:492.
- Yasui-Furukori N, Saito M, Inoue Y, et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol. 2007;63:51–56.
- Saarikoski T, Saari TI, Hagelberg NM, et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Eur J Clin Pharmacol. 2015;71:321–327.
- Wahlländer A, Paumgartner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol. 1989;37:279–283.
- Abdel-Rahman SM, Gotschall RR, Kauffman RE, et al. Investigation of terbinafine as a CYP2D6 inhibitor in vivo. Clin Pharmacol Ther. 1999;65:465–472.
- Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32:210–258.
- Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole, and terbinafine and their management. J Am Acad Dermatol. 1999;41:237–249.
- Oliveira DC, de Loreto ÉS, Mario DAN, et al. Sporothrix schenckii complex: susceptibilities to combined antifungal agents and characterization of enzymatic profiles. Rev Inst Med Trop Sao Paulo. 2015;57:289–294.
- Yilancioglu K, Weinstein ZB, Meydan C, et al. Target-independent prediction of drug synergies using only drug lipophilicity. J Chem Inf Model. 2014;54:2286–2293.
- Homa M, Galgóczy L, Tóth E, et al. In vitro antifungal activity of antipsychotic drugs and their combinations with conventional antifungals against Scedosporium and Pseudallescheria isolates. Med Mycol. 2015;53:890–895.
- Spader TB, Venturini TP, Rossato L, et al. Synergysm of voriconazole or itraconazole with other antifungal agents against species of Fusarium. Rev Iberoam Micol. 2013;30:200–204.
- Janssen Pharma. SPORANOX® (itraconazole) capsules [Internet]. Drugs@FDA; [cited 2018 Feb 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020083s048s049s050lbl.pdf **
- SPORANOX-Itraconazole (100 mg tablets) Product Monograph. Health Canada product drug data base; [cited 2018 Feb 28]; Available from:https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
- Zane LT, Chanda S, Coronado D, et al. Antifungal agents for onychomycosis: new treatment strategies to improve safety. Dermatol Online J. 2016;22:1–12.
- Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332–341.
- Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64:58–65.
- Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82:511–516.
- Lohitnavy M, Methaneethorn J, Sriarwut T, et al. A semi-mechanistic pharmacokinetic model of saquinavir combined with itraconazole in HIV-1-positive patients. Conf Proc Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf. 2015;2015:3242–3245.
- Andes D, Azie N, Yang H, et al. Drug-drug interaction associated with mold-active triazoles among hospitalized patients. Antimicrob Agents Chemother. 2016;60:3398–3406.
- Tailor SA, Gupta AK, Walker SE, et al. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol. 1996;132:350–352.
- Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 1995;333:664–665.
- Bodey GP. Azole antifungal agents. Clin Infect Dis Off Publ Infect Dis Soc Am. 1992;14:161–169.
- Yang S, Liao Y, Cong L, et al. In vitro interactions between non-steroidal anti-inflammatory drugs and antifungal agents against planktonic and biofilm forms of trichosporon asahii. PloS One. 2016;11:e0157047.
- Cordeiro R de A, de Melo CVS, Marques FJ de F, et al. Synthesis and in vitro antifungal activity of isoniazid-derived hydrazones against coccidioides posadasii. Microb Pathog. 2016;98:1–5.
- Diflucan (Fluconazole Tablets) (Fluconazole for Oral Suspension) [Internet]. Drugs @ FDA: FDA approved drug products; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019949s060\,020090s044lbl.pdf **
- Product Monograph PrACT FLUCONAZOLE [Internet]. Health Canada drug product database.; [cited 2018 Feb 28]; Available from: file:///C:/Users/sversteeg/Downloads/PM00027624%20(3).PDF
- Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166:353–367.
- Gupta AK, Foley KA, Versteeg SG. New antifungal agents and new formulations against dermatophytes. Mycopathologia. 2017;182:127–141.
- CANESORAL® FROM THE MAKERS OF CANESTEN® [Internet]. Canesten; [cited 2018 Feb 28]; Available from: https://www.canesten.ca/en/canesoral-from-the-makers-of-canesten.php
- Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38:111–180.
- Sun G, Thai S-F, Lambert GR, et al. Fluconazole-induced hepatic cytochrome P450 gene expression and enzymatic activities in rats and mice. Toxicol Lett. 2006;164:44–53.
- Cadle RM, Zenon GJ, Rodriguez-Barradas MC, et al. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother. 1994;28:191–195.
- Hsiao S-H, Chang H-J, Hsieh T-H, et al. Rhabdomyolysis caused by the moderate CYP3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review. J Clin Pharm Ther. 2016;41:575–578.
- Su Y-C, Wu -C-C. Colchicine-induced acute neuromyopathy in a patient using concomitant fluconazole: case report and literature review. Drug Saf - Case Rep. 2015;2:16.
- Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol. 1996;42:465–470.
- Touchette MA, Chandrasekar PH, Milad MA, et al. Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. Br J Clin Pharmacol. 1992;34:75–78.
- Kang BC, Yang CQ, Cho HK, et al. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. Biopharm Drug Dispos. 2002;23:77–81.
- Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol. 1998;53:445–449.
- Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991;114:755–757.
- Taveira GB, Carvalho AO, Rodrigues R, et al. Thionin-like peptide from capsicum annuum fruits: mechanism of action and synergism with fluconazole against Candida species. BMC Microbiol. 2016;16:12.
- Liu S, Yue L, Gu W, et al. Synergistic effect of fluconazole and calcium channel blockers against resistant Candida albicans. PloS One. 2016;11:e0150859.
- Reichert-Lima F, Busso-Lopes AF, Lyra L, et al. Evaluation of antifungal combination against Cryptococcus spp. Mycoses. 2016;59:585–593.
- Movahed E, Tan GMY, Munusamy K, et al. Triclosan demonstrates synergic effect with amphotericin b and fluconazole and induces apoptosis-like cell death in cryptococcus neoformans. Front Microbiol. 2016;7:360.
- Noxafil® (posaconazole) injection 18 mg/mL Noxafil® (posaconazole) delayed-release tablets 100 mg Noxafil® (posaconazole) oral suspension 40 mg/mL [Internet].FDA U.S. Food and Drug Administration; [cited 2017 Jan 17]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf **
- Posanol (posaconazole) Product Monograph [Internet]. Health Canada drug product database; [cited 2017 Jan 17]; Available from: file:///C:/Users/sversteeg/Downloads/PM00035032%20(1).PDF
- Dunand J, Viguie C, Paugam A. Intermittent posaconazole regimen to treat superficial Scytalidium dimidiatum infection. Eur J Dermatol EJD. 2010;20:649–650.
- Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012;166:389–398.
- Munayyer HK, Mann PA, Chau AS, et al. Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds. Antimicrob Agents Chemother. 2004;48:3690–3696.
- Krishna G, Ma L, Prasad P, et al. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin Drug Metab Toxicol. 2012;8:1–10.
- Cho E, Chan H, Nguyen HM, et al. Management of drug interaction between posaconazole and sirolimus in patients who undergo hematopoietic stem cell transplant. Pharmacotherapy. 2015;35:578–585.
- Petitcollin A, Crochette R, Tron C, et al. Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole. Drug Metab Pharmacokinet. 2016;31:389–393.
- Jeong W, Haywood P, Shanmuganathan N, et al. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. J Antimicrob Chemother. 2016;71:3540–3547.
- Lempers VJC, Van Den Heuvel JJMW, Russel FGM, et al. Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016;60:3372–3379.
- Morcos PN, Cleary Y, Guerini E, et al. Clinical drug-drug interactions through cytochrome p450 3a (cyp3a) for the selective ALK inhibitor alectinib. Clin Pharmacol Drug Dev. 2017;6:280–291.
- Walravens J, Brouwers J, Spriet I, et al. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50:725–734.
- Narreddy S, Manavathu E, Chandrasekar PH, et al. In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes. J Antimicrob Chemother. 2010;65:701–703.
- Martin-Vicente A, Capilla J, Guarro J. Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis. Med Mycol. 2017;55:457–460.
- Sun W, He S, Martínez-Romero C, et al. Synergistic drug combination effectively blocks Ebola virus infection. Antiviral Res. 2017;137:165–172.
- GRIS-PEG® (GRISEOFULVIN ULTRAMICROSIZE) TABLETS [Internet]. FDA U.S. Food and Drug Administration; [cited 2018 Feb 26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050475s057lbl.pdf **
- Kyriakidis I, Tragiannidis A, Munchen S, et al. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16:149–165.
- Rathinasamy K, Jindal B, Asthana J, et al. Griseofulvin stabilizes microtubule dynamics, activates p53 and inhibits the proliferation of MCF-7 cells synergistically with vinblastine. BMC Cancer. 2010;10:213.
- Denk H, Abdelfattah-Gad M, Eckerstorfer R, et al. Microsomal mixed-function oxidase and activities of some related enzymes in hyperplastic nodules induced by long-term griseofulvin administration in mouse liver. Cancer Res. 1980;40:2568–2573.
- Cheng Y-C, Tsai M-C, Huang M-C. Delirium associated with griseofulvin and disulfiram coadministration. J Clin Psychopharmacol. 2015;35:477–478.
- Fagerberg JH, Sjögren E, Bergström CAS. Concomitant intake of alcohol may increase the absorption of poorly soluble drugs. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2015;67:12–20.
- Bickers DR. Antifungal therapy: potential interactions with other classes of drugs. J Am Acad Dermatol. 1994;31:S87–90.
- Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis [Internet]. BusinessWire; [cited 2017 Jan 30]; Available from: http://www.businesswire.com/news/home/20170106005121/en/
- Sigurgeirsson B, Van Rossem K, Malahias S, et al. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol. 2013;69:416–425.
- VFEND® (voriconazole) Tablets, Oral Suspension, and I.V. [Internet]. Drugs@FDA; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s035,021267s040,021630s026lbl.pdf
- VFEVD-Voriconazole (50, 200 mg tablets) Product monograph. Health Canada product drug database; [cited 2018 Feb 28]; Available from: https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
- Gautier-Veyret E, Fonrose X, Stanke-Labesque F. Pharmacogenetics of voriconazole: CYP2C19 but also cyp3a4 need to be genotyped. Clin Pharmacol Ther. 2017;102:189.
- Walsh TJ, Moriyama B, Penzak SR, et al. Response to “pharmacogenetics of voriconazole: cyp2c19 but also cyp3a4 need to be genotyped” – the role of cyp3a4 and cyp3a5 polymorphisms in clinical pharmacokinetics of voriconazole. Clin Pharmacol Ther. 2017;102:190.
- He H-R, Sun J-Y, Ren X-D, et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2015;34:811–819.
- Zhu L, Brüggemann RJ, Uy J, et al. CYP2C19 genotype-dependent pharmacokinetic drug interaction between voriconazole and ritonavir-boosted atazanavir in healthy subjects. J Clin Pharmacol. 2017;57:235–246.
- Canesten 1% Topical Cream (Clotrimazole) Product Monograph [Internet]. Health Canada drug product databse; [cited 2017 Jun 20]; Available from: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=19487
- Lotrison (clotrimazole and betamethasone dipropionate) cream 1%/0.05%, for topical use [Internet]. FDA U.S. Food and Drug Administration; [cited 2017 Jun 20]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018827s046lbl.pdf *
- Micatin Cream Micatin Powder Micatin Spray Powder Product Monograph [Internet]. Health Canada drug product database; [cited 2017 Jun 20]; Available from: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=49064
- Vusion (0.25% microazole nitrate, 15% zinc oxide, and 81.35% white petrolatum) ointment [Internet]. FDA U.S. Food and Drug Administration; [cited 2017 Jun 20]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021026 *
- JUBLIA® (efinaconazole) topical solution, 10% [Internet]. Drugs@FDA; [cited 2014 Sep 17]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf *
- LP. PrJUBLIATM Efinaconazole Topical Solution, 10% w/w Topical Antifungal Agent. Health Canada drug product database; [cited 2018 Feb 28]; Available from: https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
- Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis. J Drugs Dermatol JDD. 2013;12:1010–1016.
- ERTACZO (SERTACONAZOLE NITRATE) CREAM, 2% [Internet]. Drugs@FDA; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21385_Ertaczo_lbl.pdf *
- LUZU (luliconazole) Cream, 1% for topical use [Internet]. Drugs @ FDA: FDA Approved Drug Products; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204153s000lbl.pdf *
- Jones T, Tavakkol A. Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis. Antimicrob Agents Chemother. 2013;57:2684–2689.
- NAFTIN (naftifine hydrochloride) cream, 2%, for topical use [Internet]. FDA U.S. Food and Drug Administration; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019599s013lbl.pdf *
- Mentax (butenafine HCl cream) Cream, 1% [Internet]. FDA U.S. Food and Drug Administration; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20524s5lbl.pdf *
- Tinactin® Once-A-DayTM Cream BUTENAFINE HYDROCHLORIDE CREAM 1% Topical Antifungal Agent [Internet]. Health Canada drug product databse; [cited 2017 Jun 19]; Available from: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68279
- Loprox Cream (cicloporix) 0.77% [Internet]. Drugs@FDA: FDA Approved Drug Products; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018748s024,019824s023,020519s016lbl.pdf *
- Valeant Canada LP. PENLACTM (Ciclopirox Topical Solution, 8% w/w) NAIL LACQUER. Health Canada Drug Product Database; [cited 2018 Feb 28]; Available from: https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
- Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol. 2000;43:S57–69.
- KERYDIN(TM) (tavaborole) topical solution, 5% [Internet]. US Food and Drug Administration; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails *
- Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British society for medical mycology. J Antimicrob Chemother. 2014;69:1162–1176.
- Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med Berl Ger. 1995;73:539–553.
- Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693–715.
- Abarca J, Colon LR, Wang VS, et al. Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies. J Manag Care Pharm JMCP. 2006;12:383–389.
- Dechanont S, Maphanta S, Butthum B, et al. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23:489–497.
- Hansten P, Horn J. The top 100 drug interactions: a guide to patient management. Charleston, South Carolina: CreateSpace Independent Publishing Platform; 2016.
- CRESEMBA® (isavuconazonium sulfate) [Internet]. FDA U.S. Food and Drug Administration; [cited 2017 Jun 26]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207500
- Cresemba Isavuconazole [Internet]. European medicines agency science medicines health; 2015 [cited 2017 Jun 26]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002734/human_med_001907.jsp&mid=WC0b01ac058001d124
- Donnelley MA, Zhu ES, Thompson GR. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79–86.
- Abelcet (Amphotericin B Lipid Complex Injection) 5 mg Amphotericin B/mL: 20 mL Vial Injectable Suspension Antifungal [Internet]. Health Canada. Drug Product Database; [cited 2017 Jun 26]; Available from: https://pdf.hres.ca/dpd_pm/00010135.PDF
- AmBisome (amphotericin B) liposome for injection [Internet]. Drugs @ FDA: FDA Approved Drug Products; [cited 2018 Feb 28]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf
- CANCIDAS® (caspofungin acetate) for injection, for intravenous use [Internet]. FDA U.S. Food and Drug Administration; [cited 2017 Jun 26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021227s034s035lbl.pdf
- CANCIDAS® Caspofungin for injection, 50 mg/vial, 70 mg/vial (as caspofungin actetate) Antifungal [Internet]. Health Canada. drug product database; [cited 2017 Jun 26]; Available from: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=68232
- Penlac, Ciclopirox (topical solution 8% w/w) Product monograph [internet]. Health Canada product drug database; [cited 2018 Feb 28]; Available from: https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do
- Efinaconazole Topical Solution, 10% w/w Topical Antifungal Agent [Internet]. Health Canada. drug product database; [cited 2017 Feb 7] Available from: https://health-products.canada.ca/dpd-bdpp/dispatch-repartition.do;jsessionid=08E72580F8EF838FAC8935683D569430
- Elewski BE, Aly R, Baldwin SL, et al. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: results from 2 randomized phase-III studies. J Am Acad Dermatol. 2015;73:62–69.
- Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68:600–608.
- Lipner SR, Scher RK. Management of onychomycosis and co-existing tinea pedis. J Drugs Dermatol JDD. 2015;14:492–494.